Seer (SEER) Profit After Tax (2020 - 2026)
Seer (SEER) posted quarterly Profit After Tax of -$17.4 million for Q1 2026, up 12.23% year-over-year from -$15.5 million in Q1 2025, and down 6.57% quarter-over-quarter from -$16.3 million in Q4 2025.
Seer (SEER) Profit After Tax (2020 - 2026) Analysis & Trends
Seer's Profit After Tax history runs 7 years deep, the most recent figure standing at -$17.4 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 12.23% year-over-year to -$17.4 million; the TTM figure through Mar 2026 stood at -$71.2 million (up 17.57% YoY), while the FY2025 annual figure was -$73.6 million, up 14.69% from the prior year.
- Profit After Tax for Q1 2026 stood at -$17.4 million, down from -$16.3 million in the prior quarter.
- The five-year high for Profit After Tax was -$16.3 million in Q4 2025, with the low at -$24.0 million in Q1 2023.
- The 5-year median for Profit After Tax is -$20.9 million (2023), against an average of -$20.9 million.
- The sharpest annual moves came in 2022 and 2025: Profit After Tax slumped 43.7% in 2022, then climbed 27.27% in 2025.
- Seer's Profit After Tax stood at -$20.4 million in 2022, then rose by 12.83% to -$17.8 million in 2023, then retreated by 26.14% to -$22.4 million in 2024, then gained by 27.27% to -$16.3 million in 2025, then slipped by 6.57% to -$17.4 million in 2026.
- Business Quant data shows SEER's Profit After Tax at -$17.4 million in Q1 2026, -$16.3 million in Q4 2025, and -$18.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Seer | 230.63 Mn | 230.63 Mn | 1.51 Mn | -17.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.17 Mn |
| Mar 31, 2026 | -17.36 Mn |
| Dec 31, 2025 | -16.29 Mn |
| Sep 30, 2025 | -18.11 Mn |
| Jun 30, 2025 | -19.42 Mn |
| Mar 31, 2025 | -19.78 Mn |
| Dec 31, 2024 | -22.40 Mn |
| Sep 30, 2024 | -21.33 Mn |
| Jun 30, 2024 | -22.85 Mn |
| Mar 31, 2024 | -20.68 Mn |
| Dec 31, 2023 | -17.75 Mn |
| Sep 30, 2023 | -20.85 Mn |
| Jun 30, 2023 | -23.43 Mn |
| Mar 31, 2023 | -23.96 Mn |
| Dec 31, 2022 | -20.37 Mn |
| Sep 30, 2022 | -23.56 Mn |
| Jun 30, 2022 | -22.82 Mn |
| Mar 31, 2022 | -23.65 Mn |
| Dec 31, 2021 | -19.74 Mn |
| Sep 30, 2021 | -18.39 Mn |